Q-omics provides the consensus-scored ADGRF5P2 profile across patient tissues and cancer cell-line models. ADGRF5P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADGRF5P2 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, ADGRF5P2 RNA expression shows 13,364 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where ADGRF5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRF5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRF5P2 survival associations across molecular data types. ADGRF5P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRF5P2 RNA expression–survival associations across cancer types. High ADGRF5P2 expression shows unfavorable associations in STAD, BLCA and CESC, but favorable associations in KIRC, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADGRF5P2 RNA expression.
This table summarizes ADGRF5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ADGRF5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRF5P2 shows lower tumor expression in LUAD, KIRP, LUSC, BRCA, UCEC and PAAD. The LUAD box plot shows higher ADGRF5P2 RNA expression in normal versus tumor tissue (log2 FC = −0.556, t-test p < 0.001).
This table shows molecular features associated with ADGRF5P2 in patient tissues and cancer cell lines. In patient samples, ADGRF5P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
